(FME) Fresenius Medical Care - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005785802
FME: Dialysis, Medical Equipment, Pharmaceuticals, Clinics, Services
Fresenius Medical Care AG & Co. KGaA (XETRA:FME) is a global leader in the provision of dialysis and related services for patients with renal diseases. The company operates a vast network of outpatient dialysis clinics worldwide, offering comprehensive care that includes hemodialysis, peritoneal dialysis, and associated laboratory services. Additionally, Fresenius Medical Care provides critical support services such as clinical monitoring, patient education, and home delivery of essential supplies, ensuring continuous care for patients with end-stage renal disease (ESRD) and acute kidney failure. Its services extend to hospitals, where it delivers dialysis treatment for inpatients under contractual agreements.
Beyond its clinical services, Fresenius Medical Care is a major developer, manufacturer, and distributor of medical products tailored to renal care. Its product portfolio includes polysulfone dialyzers, hemodialysis machines, peritoneal dialysis solutions, and water treatment systems. The company also specializes in renal pharmaceuticals, offering a range of medications for patients with kidney diseases. Its distribution network spans dialysis clinics, hospitals, and specialized treatment centers, leveraging both in-house sales teams and external partners to ensure global reach.
As a key player in the healthcare industry, Fresenius Medical Care has established itself as a pioneer in innovation and patient-centric care. Its commitment to advancing renal therapy is evident in its continuous investment in research and development, ensuring that patients receive cutting-edge treatments. The companys integrated approach, combining clinical services with product innovation, positions it as a critical provider in the global healthcare landscape.
Based on the provided technical and fundamental data, Fresenius Medical Care AG & Co. KGaA (XETRA:FME) is expected to experience the following trends over the next three months:
From a technical perspective, the stock is currently trading below its SMA20 and SMA50 levels, which are at 44.00 and 44.56 respectively, indicating potential near-term weakness. The SMA200 at 40.78 provides a key support level. The ATR of 1.45 suggests moderate volatility, which may stabilize as the stock consolidates.
Fundamentally, the companys forward P/E of 11.55 indicates market expectations of earnings growth, which could support a recovery in the stock price. The P/B ratio of 0.84 and P/S ratio of 0.63 suggest undervaluation relative to book value and sales, respectively. However, the RoE of 3.69% reflects modest profitability, which may impact near-term price appreciation.
Over the next three months, the stock is likely to consolidate within a range defined by the SMA200 support at 40.78 and resistance at the SMA50 level of 44.56. A breakout above the SMA50 could signal a bullish reversal, while a breach of the SMA200 may indicate further downside. The low ATR suggests reduced volatility, which could lead to a tighter trading range. The fundamental outlook, supported by the attractive valuations, may provide a floor for the stock during this period.
Additional Sources for FME Stock
FME Stock Overview
| Market Cap in USD | 14,628m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
FME Stock Ratings
| Growth Rating | -21.1 |
| Fundamental | 16.1 |
| Dividend Rating | 37.0 |
| Rel. Strength | 15.6 |
| Analysts | - |
| Fair Price Momentum | 42.12 EUR |
| Fair Price DCF | 146.78 EUR |
FME Dividends
| Dividend Yield 12m | 6.33% |
| Yield on Cost 5y | 4.32% |
| Annual Growth 5y | -13.09% |
| Payout Consistency | 97.7% |
FME Growth Ratios
| Growth Correlation 3m | -68% |
| Growth Correlation 12m | 72.6% |
| Growth Correlation 5y | -70.9% |
| CAGR 5y | -6.33% |
| CAGR/Max DD 5y | -0.10 |
| Sharpe Ratio 12m | 1.38 |
| Alpha | 8.31 |
| Beta | 0.370 |
| Volatility | 30.71% |
| Current Volume | 676.5k |
| Average Volume 20d | 647.1k |
As of April 30, 2025, the stock is trading at EUR 43.74 with a total of 676,479 shares traded.
Over the past week, the price has changed by +3.94%, over one month by -4.16%, over three months by -8.91% and over the past year by +16.49%.
Neither. Based on ValueRay Fundamental Analyses, Fresenius Medical Care is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 16.12 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FME as of April 2025 is 42.12. This means that FME is currently overvalued and has a potential downside of -3.7%.
Fresenius Medical Care has no consensus analysts rating.
According to ValueRays Forecast Model, FME Fresenius Medical Care will be worth about 45.5 in April 2026. The stock is currently trading at 43.74. This means that the stock has a potential upside of +4%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 47.4 | 8.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 45.5 | 4% |